Free Trial

Eli Lilly and Company (LLY) Stock Price, News & Analysis

Eli Lilly and Company logo
$755.32 +3.33 (+0.44%)
Closing price 09/22/2025 03:58 PM Eastern
Extended Trading
$755.40 +0.08 (+0.01%)
As of 08:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Eli Lilly and Company Stock (NYSE:LLY)

Advanced

Key Stats

Today's Range
$746.27
$762.04
50-Day Range
$625.15
$811.73
52-Week Range
$623.78
$939.30
Volume
2.52 million shs
Average Volume
3.39 million shs
Market Capitalization
$714.88 billion
P/E Ratio
49.37
Dividend Yield
0.79%
Price Target
$939.61
Consensus Rating
Moderate Buy

Company Overview

Eli Lilly and Company Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
100th Percentile Overall Score

LLY MarketRank™: 

Eli Lilly and Company scored higher than 100% of companies evaluated by MarketBeat, and ranked 4th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Eli Lilly and Company has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 14 buy ratings, 9 hold ratings, and no sell ratings.

  • Upside Potential

    Eli Lilly and Company has a consensus price target of $939.61, representing about 24.4% upside from its current price of $755.32.

  • Amount of Analyst Coverage

    Eli Lilly and Company has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Eli Lilly and Company's stock forecast and price target.
  • Earnings Growth

    Earnings for Eli Lilly and Company are expected to grow by 32.54% in the coming year, from $23.48 to $31.12 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Eli Lilly and Company is 49.37, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 298.14.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Eli Lilly and Company is 49.37, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 348.73.

  • Price to Earnings Growth Ratio

    Eli Lilly and Company has a PEG Ratio of 1.05. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Eli Lilly and Company has a P/B Ratio of 50.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Eli Lilly and Company's valuation and earnings.
  • Percentage of Shares Shorted

    0.95% of the float of Eli Lilly and Company has been sold short.
  • Short Interest Ratio / Days to Cover

    Eli Lilly and Company has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Eli Lilly and Company has recently decreased by 7.59%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Eli Lilly and Company has a dividend yield of 0.80%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Eli Lilly and Company has been increasing its dividend for 11 years.

  • Dividend Coverage

    The dividend payout ratio of Eli Lilly and Company is 39.22%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Eli Lilly and Company will have a dividend payout ratio of 19.28% next year. This indicates that Eli Lilly and Company will be able to sustain or increase its dividend.

  • Read more about Eli Lilly and Company's dividend.
  • Percentage of Shares Shorted

    0.95% of the float of Eli Lilly and Company has been sold short.
  • Short Interest Ratio / Days to Cover

    Eli Lilly and Company has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Eli Lilly and Company has recently decreased by 7.59%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Eli Lilly and Company has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 166 news articles for Eli Lilly and Company this week, compared to 78 articles on an average week.
  • Search Interest

    Only 224 people have searched for LLY on MarketBeat in the last 30 days. This is a decrease of -21% compared to the previous 30 days.
  • MarketBeat Follows

    Only 83 people have added Eli Lilly and Company to their MarketBeat watchlist in the last 30 days. This is a decrease of -28% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Eli Lilly and Company insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,894,841.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 0.14% of the stock of Eli Lilly and Company is held by insiders.

  • Percentage Held by Institutions

    82.53% of the stock of Eli Lilly and Company is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Eli Lilly and Company's insider trading history.
Receive LLY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eli Lilly and Company and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LLY Stock News Headlines

Eli lilly logo on cellphone
Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything
Eli Lilly stock rises on FDA fast-track hopes for its oral GLP-1 obesity drug and $27B U.S. manufacturing expansion; it's a tough trade but solid long-term hold...
Vanguard Logo on cellphone
Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio (LLY)
The Vanguard Growth ETF provides concentrated exposure to the market's most innovative giants and has a proven history of strong, long-term returns.
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.tc pixel
This photo shows Novo Nordisk headquarters in Bagsvaerd, Denmark, on February 5, 2025
Novo Nordisk, maker of obesity drug Wegovy, to cut 9,000 jobs to sharpen focus, meet competition
Danish pharmaceutical company Novo Nordisk, maker of weight-loss drug Wegovy, said Wednesday it would cut 9,000 jobs, 5,000 of them in Denmark, in order to strengthen the company’s focus on growth opportunities in obesity and diabetes medications...
Major Shareholder Cashes In on Eli Lilly & Co Stock!
See More Headlines

LLY Stock Analysis - Frequently Asked Questions

Eli Lilly and Company's stock was trading at $772.00 at the start of the year. Since then, LLY shares have decreased by 2.2% and is now trading at $755.3230.

Eli Lilly and Company (NYSE:LLY) announced its quarterly earnings data on Thursday, August, 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. The company's quarterly revenue was up 37.6% on a year-over-year basis.
Read the conference call transcript
.

Eli Lilly and Company's board initiated a stock buyback program on Monday, December 9th 2024, which authorizes the company to repurchase $15,000,000,000 in shares, according to EventVestor. This means that the company could reacquire up to 2% of its shares through open market purchases. Shares buyback programs are often a sign that the company's board believes its stock is undervalued.

Eli Lilly and Company subsidiaries include these companies: Protomer Technologies, Prevail Therapeutics Inc., Disarm Therapeutics, Disarm Therapeutics, Dermira, Loxo Oncology, CoLucid Pharmaceuticals, and others.

Eli Lilly and Company's top institutional investors include Vanguard Group Inc. (8.48%), PNC Financial Services Group Inc. (5.41%), State Street Corp (3.65%) and Geode Capital Management LLC (1.91%). Insiders that own company stock include Lilly Endowment Inc, David A Ricks, Daniel Skovronsky, J Erik Fyrwald, Anne E White, Patrik Jonsson, Johna Norton, Jamere Jackson, Alonzo Weems, Donald A Zakrowski, Gabrielle Sulzberger and Acquisition Corp Kearny.
View institutional ownership trends
.

Shares of LLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Eli Lilly and Company investors own include Broadcom (AVGO), NVIDIA (NVDA), Meta Platforms (META), BlackRock (BLK), Salesforce (CRM), Chevron (CVX) and ServiceNow (NOW).

Company Calendar

Last Earnings
8/07/2025
Record date for 9/10 Dividend
8/15/2025
Ex-Dividend for 9/10 Dividend
8/15/2025
Dividend Payable
9/10/2025
Today
9/23/2025
Next Earnings (Estimated)
10/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Large Cap Pharma
Sub-Industry
Pharmaceuticals
Current Symbol
NYSE:LLY
CIK
59478
Employees
47,000
Year Founded
1876

Price Target and Rating

High Price Target
$1,190.00
Low Price Target
$700.00
Potential Upside/Downside
+24.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
24 Analysts

Profitability

EPS (Trailing Twelve Months)
$15.30
Trailing P/E Ratio
49.37
Forward P/E Ratio
32.17
P/E Growth
1.05
Net Income
$10.59 billion
Net Margins
25.91%
Pretax Margin
31.66%
Return on Equity
92.72%
Return on Assets
16.89%

Debt

Debt-to-Equity Ratio
1.86
Current Ratio
1.28
Quick Ratio
1.00

Sales & Book Value

Annual Sales
$45.04 billion
Price / Sales
15.87
Cash Flow
$14.30 per share
Price / Cash Flow
52.83
Book Value
$15.03 per share
Price / Book
50.25

Miscellaneous

Outstanding Shares
946,460,000
Free Float
945,132,000
Market Cap
$714.88 billion
Optionable
Optionable
Beta
0.47

Social Links

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NYSE:LLY) was last updated on 9/23/2025 by MarketBeat.com Staff
From Our Partners